Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T14:57:48.071Z.
Calculation as of: 2026-10-06T14:57:48.071Z.
Quote observation: 2026-10-06T14:55:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5a8aae8e93f82a899e51ff603ce0499f2ee8a4244ac8b174beef8711f00adb15
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$53.81M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$57.49M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$52.68M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Spectral AI, Inc. (MDAI) | $55.14M | N/A | N/A | N/A | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $53.81M | N/A | N/A | N/A | N/A |
| Aldeyra The (ALDX)vs › | $56.10M | N/A | N/A | N/A | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.78M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $53.09M | N/A | N/A | N/A | N/A |
| ImageneBio Inc (IMA)vs › | $53.01M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $57.49M | N/A | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.54M | N/A | N/A | N/A | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $52.68M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $52.49M | 9.14x | 5.34x | 6.36x | 5.55x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
